[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"LivaNova USA, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":54},{"warningLetters":4,"total":53},[5,31],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},348,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-02-03T05:00:00Z\">02\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-10T04:00:00Z\">09\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feniva-usa-inc-706565-09102025\">Eniva USA, Inc.\u003C\u002Fa>","Human Foods Program","CGMP\u002FDietary Supplement\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Andrew J Baechler\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Eniva USA, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2700 Campus Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Plymouth\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55441-2601\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:andyb@eniva.com\"> andyb@eniva.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 10, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #706565\u003C\u002Fp>\u003Cp>Dear Mr. Baechler:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 2700 Campus Dr., Plymouth, MN, from November 19, 2024, through January 13, 2025. Based on inspectional findings and review of product labels collected during the inspections, as well as review of your website, www.eniva.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on January 13, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your response on February 5, 2025, and we address your response below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility from November 19, 2024, through January 13, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your Immune Support (previously called Cold Buster) and Ashwagandha Gummies dietary supplements to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1) You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplements, as required by 21 CFR 111.70(e). During the inspection, your Senior Quality Manager stated that your finished product specifications are maintained in the form of blank “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” documents. However, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” documents do not establish product specifications that confirm the identity, purity, strength, and composition of the finished batches of your Cold Buster (now Immune Support) and Ashwagandha Gummies dietary supplements. Specifically:\u003C\u002Fp>\u003Cul>\u003Cli>Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” document for your Cold Buster (now Immune Support) lists appearance, color, odor, conductivity, pH, percent solids, and specific gravity as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” These factors do not constitute unique criteria that can confirm the identity of the Cold Buster product. Additionally, these factors do not—either alone or in conjunction—evaluate the purity, strength, and composition of this finished product.\u003C\u002Fli>\u003Cli>Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” document for your Ashwaghanda Gummies lists appearance, color, odor, and water activity as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” These factors do not constitute unique criteria that can confirm the identity of the Ashwaghanda Gummies product. Additionally, these factors do not—either alone or in conjunction—evaluate the purity, strength, and composition of this finished product.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your response to the FDA Form 483, received February 5, 2025, and find it does not adequately address the violation. In your response, you stated that you plan to update finished product specification forms for the finished dietary supplement products you manufacture, including Immune Support and Ashwagandha Gummies. However, to date, you have not submitted any evidence of further corrective action.\u003C\u002Fp>\u003Cp>2) You failed to make and keep documentation of any material review and disposition decision and follow-up, as required by 21 CFR 111.140(b)(3). Specifically, your Senior Quality Manager stated that when “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” results had been encountered by your firm since your last inspection for incoming components and outgoing dietary supplements, you failed to document the investigation, findings, material review by quality, and the disposition of affected materials.\u003C\u002Fp>\u003Cp>We have reviewed your response to the FDA Form 483, received February 5, 2025, and find it does not adequately address the violation. In your response, you stated that you will review and update your SOP QS-009, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and proceed to document all investigations. However, to date, you have not submitted any evidence of corrective action.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>In addition to the above-mentioned violations, we also have the following comment:\u003C\u002Fp>\u003Cp>We conducted a case assessment and review of your firm’s response regarding observation 1, namely 21 CFR 114.83 for acid foods. Your response to this observation appears inadequate. We request the following be addressed by your firm:\u003C\u002Fp>\u003Cul>\u003Cli>Is management able to furnish the supporting documents from the University of Minnesota which support the conclusion that these products are acid foods?\u003C\u002Fli>\u003Cli>Has management made formulation changes to the following original four products: Vibe Original, Vibe 2.0, Vibe Apple and Vibe Kids?\u003C\u002Fli>\u003Cli>Has management fully evaluated the other products, not listed above, to determine if they are acidified or acid food products?\u003C\u002Fli>\u003Cli>Please provide a list of ingredients, pH for all ingredients, formulation, and finished product pH for the Vibe product for review. Does your firm add acid ingredients to shift the product pH? What is the pH of the product before acidulent is added?\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Rebecca Allen, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #706565 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nAndrew J Baechler\n\nRecipient Title\n\nCEO\n\nEniva USA, Inc.\n\n2700 Campus Dr.\n\nPlymouth, MN 55441-2601\n\nUnited States\n\nandyb@eniva.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nSeptember 10, 2025\nWARNING LETTER\nCMS #706565\nDear Mr. Baechler:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 2700 Campus Dr., Plymouth, MN, from November 19, 2024, through January 13, 2025. Based on inspectional findings and review of product labels collected during the inspections, as well as review of your website, www.eniva.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on January 13, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your response on February 5, 2025, and we address your response below.\nAdulterated Dietary Supplements\nThe inspection of your facility from November 19, 2024, through January 13, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your Immune Support (previously called Cold Buster) and Ashwagandha Gummies dietary supplements to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\nYour significant violations of the CGMP requirements are as follows:\n1) You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplements, as required by 21 CFR 111.70(e). During the inspection, your Senior Quality Manager stated that your finished product specifications are maintained in the form of blank “(b)(4)” documents. However, your “(b)(4)” documents do not establish product specifications that confirm the identity, purity, strength, and composition of the finished batches of your Cold Buster (now Immune Support) and Ashwagandha Gummies dietary supplements. Specifically:\nYour “(b)(4)” document for your Cold Buster (now Immune Support) lists appearance, color, odor, conductivity, pH, percent solids, and specific gravity as “(b)(4).” These factors do not constitute unique criteria that can confirm the identity of the Cold Buster product. Additionally, these factors do not—either alone or in conjunction—evaluate the purity, strength, and composition of this finished product.\nYour “(b)(4)” document for your Ashwaghanda Gummies lists appearance, color, odor, and water activity as “(b)(4).” These factors do not constitute unique criteria that can confirm the identity of the Ashwaghanda Gummies product. Additionally, these factors do not—either alone or in conjunction—evaluate the purity, strength, and composition of this finished product.\nWe have reviewed your response to the FDA Form 483, received February 5, 2025, and find it does not adequately address the violation. In your response, you stated that you plan to update finished product specification forms for the finished dietary supplement products you manufacture, including Immune Support and Ashwagandha Gummies. However, to date, you have not submitted any evidence of further corrective action.\n2) You failed to make and keep documentation of any material review and disposition decision and follow-up, as required by 21 CFR 111.140(b)(3). Specifically, your Senior Quality Manager stated that when “(b)(4)” results had been encountered by your firm since your last inspection for incoming components and outgoing dietary supplements, you failed to document the investigation, findings, material review by quality, and the disposition of affected materials.\nWe have reviewed your response to the FDA Form 483, received February 5, 2025, and find it does not adequately address the violation. In your response, you stated that you will review and update your SOP QS-009, “(b)(4),” and proceed to document all investigations. However, to date, you have not submitted any evidence of corrective action.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nIn addition to the above-mentioned violations, we also have the following comment:\nWe conducted a case assessment and review of your firm’s response regarding observation 1, namely 21 CFR 114.83 for acid foods. Your response to this observation appears inadequate. We request the following be addressed by your firm:\nIs management able to furnish the supporting documents from the University of Minnesota which support the conclusion that these products are acid foods?\nHas management made formulation changes to the following original four products: Vibe Original, Vibe 2.0, Vibe Apple and Vibe Kids?\nHas management fully evaluated the other products, not listed above, to determine if they are acidified or acid food products?\nPlease provide a list of ingredients, pH for all ingredients, formulation, and finished product pH for the Vibe product for review. Does your firm add acid ingredients to shift the product pH? What is the pH of the product before acidulent is added?\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Rebecca Allen, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #706565 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Eniva USA, Inc.","eniva-usa-inc-706565-09102025","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feniva-usa-inc-706565-09102025","2026-10-26T08:08:35.579466+00:00","Warning Letter","Issued","2026-02-03","706565","Dietary Supplements","Andrew J Baechler","2026-08-19T05:07:51.096+00:00","Via Email","2025-09-10",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},3361,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2021-05-11T13:20:00Z\">05\u002F11\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-30T04:00:00Z\">04\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fj-l-usa-inc-613754-04302021\">J &amp; L USA Inc.\u003C\u002Fa>","Division of West Coast Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sam Sanwei Liang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>J &amp; L USA Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6541 E Washington Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Commerce\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90040-1821\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 30, 2021\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 613754\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Liang:\u003C\u002Fp>\n\n\u003Cp>On January 19, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of FSVP records that you submitted to FDA electronically for your firm J &amp; L USA Inc., located at 6541 E Washington Blvd., Commerce, CA 90040-1821. We also conducted an inspection on May 31, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the Foreign Supplier Verification Program (FSVP) implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During our inspections, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for Green Tea and Dried Bamboo Leaf imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Dried White Fungus imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, we found that you are still not in compliance with the requirements of 21 CFR Part 1 subpart L for the Rock Candy and Brown Candy in Pieces imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the previous inspection. Your firm did not have FSVPs for these food products. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of both the initial FSVP inspection on May 31, 2019 and the current inspection on January 19, 2021, our investigator provided you with Form FDA 483a, FSVP Observations. We have not received your response to either Form FDA 483a.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, your firm did not develop an FSVP for each of the following foods:\u003C\u002Fp>\n\n\u003Cp>a. Green Tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nb. Dried Bamboo Leaf imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nc. Dried White Fungus imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nd. Rock Candy imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\ne. Brown Candy in Pieces imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The above violation is not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter adequately may lead to regulatory action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of Green Tea and Dried Bamboo Leaf imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Dried White Fungus imported from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>; and Rock Candy and Brown Candy in Pieces imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> that appear to be in violation of section 805. We may place these foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to address any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Nabeela J. Chaudhry, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Nabeela Chaudhry via email at nabeela.chaudhry@fda.hhs.gov. Please reference CMS #613754 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lawton W. Lum\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSam Sanwei Liang\n\nRecipient Title\n\nGeneral Manager\n\nJ & L USA Inc.\n\n6541 E Washington Boulevard\n\nCommerce, CA 90040-1821\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nWARNING LETTER\n\nApril 30, 2021\n\nRe: CMS # 613754\n\nDear Mr. Liang:\n\nOn January 19, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of FSVP records that you submitted to FDA electronically for your firm J & L USA Inc., located at 6541 E Washington Blvd., Commerce, CA 90040-1821. We also conducted an inspection on May 31, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the Foreign Supplier Verification Program (FSVP) implementing regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring our inspections, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for Green Tea and Dried Bamboo Leaf imported from (b)(4); Dried White Fungus imported from (b)(4). Additionally, we found that you are still not in compliance with the requirements of 21 CFR Part 1 subpart L for the Rock Candy and Brown Candy in Pieces imported from (b)(4) from the previous inspection. Your firm did not have FSVPs for these food products. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of both the initial FSVP inspection on May 31, 2019 and the current inspection on January 19, 2021, our investigator provided you with Form FDA 483a, FSVP Observations. We have not received your response to either Form FDA 483a.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, your firm did not develop an FSVP for each of the following foods:\n\na. Green Tea imported from (b)(4), located in (b)(4)\n\nb. Dried Bamboo Leaf imported from (b)(4), located in (b)(4)\n\nc. Dried White Fungus imported from (b)(4), located in (b)(4)\n\nd. Rock Candy imported from (b)(4), located in (b)(4)\n\ne. Brown Candy in Pieces imported from (b)(4), located in (b)(4)\n\nThe above violation is not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter adequately may lead to regulatory action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of Green Tea and Dried Bamboo Leaf imported from (b)(4); Dried White Fungus imported from (b)(4); and Rock Candy and Brown Candy in Pieces imported from (b)(4) that appear to be in violation of section 805. We may place these foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to address any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Nabeela J. Chaudhry, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Nabeela Chaudhry via email at nabeela.chaudhry@fda.hhs.gov. Please reference CMS #613754 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nLawton W. Lum\n\nActing Program Division Director\n\nDivision of West Coast Imports","J & L USA Inc.","j-l-usa-inc-613754-04302021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fj-l-usa-inc-613754-04302021","2026-10-26T08:09:02.006209+00:00","2021-05-11","613754","Food & Beverages","Sam Sanwei Liang","2026-08-20T03:08:54.946+00:00","United Parcel Service","2021-04-30",2,{"510k":55,"classification":56,"enforcement":57,"event":58,"event_backfill":59,"pma":60,"warning_letter":61},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]